{
    "clinical_study": {
        "@rank": "90598", 
        "arm_group": [
            {
                "arm_group_label": "G-CSF alone", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will receive G-CSF for 5 consecutive days"
            }, 
            {
                "arm_group_label": "G-CSF plus plerixafor", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive G-CSF for 4 consecutive days, then receive plerixafor before the 5th dose of G-CSF"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate tumor cell mobilization (TCM) with\n      non-pegylated G-CSF alone compared with non-pegylated G-CSF plus plerixafor in patients with\n      multiple myeloma (MM) who are potentially poor mobilizers of hematopoietic stem cells (HSC).\n\n      Second objectives are to evaluate survival and disease status of G-CSF alone compared with\n      GCSF plus plerixafor, and the efficacy and safety of G-CSF plus plerixafor when used to\n      mobilize stem cells for autologous transplantation."
        }, 
        "brief_title": "An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a diagnosis of MM in partial response or complete response, who are\n             undergo an autologous hematopoietic stem cell transplantation and could be considered\n             potentially poor mobilizers.\n\n        Exclusion Criteria:\n\n          -  Does not have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to\n             1.\n\n          -  Has a history of any acute or chronic leukemia (including myelodysplastic syndrome).\n\n          -  Had prior allogeneic or autologous transplantation.\n\n          -  Less than 3 to 6 weeks since last anti-cancer therapy.\n\n          -  Chemotherapy for mobilization is not allowed.\n\n          -  Has bone marrow involvement >10% assessed based on the most recent bone marrow\n             aspirate or biopsy performed prior to first dose of G-CSF.\n\n          -  Was treated with G-CSF or other cytokine within 14 days prior to the first dose of\n             G-CSF for mobilization.\n\n          -  Has previously received plerixafor.\n\n          -  Is known to be HIV positive.\n\n          -  Has active hepatitis B or hepatitis C.\n\n          -  Has an acute infection within 24 hours prior to dosing or antibiotic therapy within 7\n             days prior to the first dose of G-CSF.\n\n          -  Has hypercalcaemia as evidenced by >1 mg/dL above upper limit of normal (ULN).\n\n          -  Previously received investigational therapy within 4 weeks of screening in this\n             protocol or currently enrolled in another investigational protocol during the\n             mobilization phase.\n\n          -  Has central nervous system involvement including brain metastases or leptomeningeal\n             disease.\n\n          -  Has an electrocardiogram (ECG) or study result indicative of cardiac ischemia or a\n             history of clinically significant rhythm disturbance(arrhythmias), or other\n             conduction abnormality.\n\n          -  Has co-morbid condition(s), which may render the patient at high risk from treatment\n             complications or impairs his/her ability to comply with the study treatment and\n             protocol.\n\n          -  Has a white blood cell (WBC) count <2.5 x 10^9/L.\n\n          -  Has an absolute neutrophil count (ANC) <1.5 x 10^9/L.\n\n          -  Has a platelet count <100 x 10^9/L.\n\n          -  Has an estimated creatine clearance \u226450 mL/min.\n\n          -  Has aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT),\n             alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT), and total\n             bilirubin \u22652.5 x ULN.\n\n          -  Does not have adequate cardiac, and pulmonary function sufficient to undergo\n             apheresis and transplantation.\n\n          -  Pregnant or breastfeeding women.\n\n          -  Does not agree to use a highly effective method of contraception while on study\n             treatment and for at least 3 months following study treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01753453", 
            "org_study_id": "ARD12858", 
            "secondary_id": [
                "MOZ23510", 
                "2011-004783-30"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "G-CSF plus plerixafor", 
                "description": "240mcg/kg, solution, subcutaneous injection", 
                "intervention_name": "Plerixafor", 
                "intervention_type": "Drug", 
                "other_name": "Mozobil,AMD3100"
            }, 
            {
                "arm_group_label": [
                    "G-CSF alone", 
                    "G-CSF plus plerixafor"
                ], 
                "description": "10 mcg/kg, solution, subcutaneous injection", 
                "intervention_name": "Granulocyte-colony stimulating factor (G-CSF)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Lenograstim", 
                "JM 3100"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hematopoietic stem cell transplantation", 
            "Tumour cell mobilization"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brugge", 
                        "country": "Belgium", 
                        "zip": "8000"
                    }, 
                    "name": "Investigational Site Number 056002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Li\u00e8ge", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "Investigational Site Number 056001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tallinn", 
                        "country": "Estonia", 
                        "zip": "13419"
                    }, 
                    "name": "Investigational Site Number 233001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vilnius", 
                        "country": "Lithuania", 
                        "zip": "LT-08661"
                    }, 
                    "name": "Investigational Site Number 440001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "14186"
                    }, 
                    "name": "Investigational Site Number 752001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ume\u00e5", 
                        "country": "Sweden", 
                        "zip": "901 85"
                    }, 
                    "name": "Investigational Site Number 752002"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Estonia", 
                "Lithuania", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot, Exploratory, Randomized, Phase 2 Safety Study Evaluating Tumor Cell (Plasma Cell) Mobilization and Apheresis Product Contamination in Plerixafor Plus Non-pegylated G-CSF Mobilized Patients and in Non-pegylated G-CSF Alone Mobilized Patients", 
        "overall_contact": {
            "email": "Contact-Us@sanofi.com", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "European Union: European Medicines Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Peripheral blood parameters", 
                "measure": "The presence of myeloma tumor cells as measured by the percentage of myeloma tumor cells/CD34+ cells", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 8 of the apheresis/treatment period"
            }, 
            {
                "description": "Peripheral blood parameters", 
                "measure": "The presence of myeloma tumor cells as measured by the percentage of myeloma tumor cells/plerixafor cumulative dose/kg body weights", 
                "safety_issue": "Yes", 
                "time_frame": "Day 5 to Day 8 of the apheresis/treatment period"
            }, 
            {
                "description": "Peripheral blood parameters", 
                "measure": "The presence of myeloma tumor cells as measured by the percentage of myeloma tumor cells/G-CSF cumulative dose/kg body weight", 
                "safety_issue": "Yes", 
                "time_frame": "Day 5 to Day 8 of the apheresis/treatment period"
            }, 
            {
                "description": "Peripheral blood parameters", 
                "measure": "The change in tumor cell mobilization(TCM) in the peripheral blood", 
                "safety_issue": "Yes", 
                "time_frame": "Day 4 pre-G-CSF to Day 5 pre-G-CSF"
            }, 
            {
                "description": "Apheresis product parameters", 
                "measure": "The number of myeloma tumor cells per patient at each apheresis", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 8 of the apheresis/treatment period"
            }, 
            {
                "description": "Apheresis product parameters", 
                "measure": "The number of patients who mobilize at least 4.5x10^5 myeloma tumor cells/kg body weight as measured in each apheresis product", 
                "safety_issue": "Yes", 
                "time_frame": "Day 5 to Day 8 of the apheresis/treatment period"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01753453"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "CD34+ stem cell yield in the apheresis product", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 8 of the apheresis/treatment period"
            }, 
            {
                "measure": "The number of patients that proceed to transplantation", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 months after final apheresis"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Day 100 post transplant and up to 2 years post first-G-CSF dose"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Genzyme, a Sanofi Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}